Sunil Xavier R.
- Country
- Norway
- Department
- Dpt of oncology
Research Overview
- Phase 3 Multicenter Randomized Study of Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated Symptomatic Splenic Marginal Zone Lymphoma
- Phase 2 Study on the Efficacy of Alpelisib and Drug Combinations in Advanced Cancer with Genomic or Protein Expression Variants in Norway
- Evaluation of Palbociclib, Olaparib, and Pertuzumab in Personalized Treatment of High-Risk Breast Cancer: A Molecular Marker-Based Clinical Trial
Data & Insights
Has run more than one trial at 15 of 55 partner sites.
Specializations
Oncology Research
The investigator specializes in breast cancer research, with particular emphasis on developing personalized therapeutic approaches for high-risk cases.
- Treatment Personalization
- High-Risk Mammary Cancer
- Molecular Biomarkers
The research focuses on identifying specific molecular indicators that can predict treatment outcomes and patient survival rates.
Precision Medicine
This investigator concentrates on advancing personalized treatment strategies through the study of molecular markers and their role in therapy response.
- Treatment Response Markers
- Resistance Mechanisms
- Therapeutic Monitoring
The work involves analyzing therapy resistance patterns and developing targeted treatment approaches.
Clinical Outcomes
The investigator studies survival outcomes in relation to molecular characteristics of breast cancer, focusing on high-risk patient populations.
- Survival Analysis
- Risk Assessment
- Treatment Effectiveness
Research encompasses identifying predictive factors for treatment success and patient prognosis.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.